Fig. 3From: Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofibanSafety of fondaparinux and enoxaparin in patients undergoing percutaneous coronary intervention. P < 0.05 was considered to indicate statistical significanceBack to article page